Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on ROCHE HOLDING LTD.
01/16 Global Lycopene Market 2017 - DSM, BASF, NIPPON, Kagome, Bayer, KIRIN, Roche ..
01/13 ROCHE : Johnson & Johnson and Alstrom Syndrome UK Address Hot Topic of Paediatri..
01/12 FOUNDATION MEDICINE : to Present at the 35th Annual J.P. Morgan Healthcare Confe..
01/12 PTC THERAPEUTICS : Announces Initiation of FIREFISH Study in Infant Type I SMA P..
01/12 CHUGAI PHARMACEUTICAL : Reports Outline Peptide Receptors Study Findings from Ch..
01/12 KITE PHARMA : Enhances Commercial Expertise with the Appointment of Ian T. Clark..
01/12 PTC THERAPEUTICS : RG7916 Granted Orphan Drug Designation in the U.S. for the Tr..
01/11 ROCHE : A Miami Mission Saves Lives in Earthquake- and Hurricane-Ravaged Haiti
01/11 FOUNDATION MEDICINE : Preliminary Q4 Revenue Rises 11 Percent
01/11 FOUNDATION MEDICINE : Steven J. Kafka Sells 8,390 Shares of Foundation Medicine,..
01/10 ROCHE : FDA Grants Genentech's Cancer Immunotherapy Tecentriq (Atezolizumab) Pri..
01/10 FOUNDATION MEDICINE : Jason Ryan Sells 4,665 Shares of Foundation Medicine, Inc...
01/10 ROCHE : FDA approves Roche's assay to assess ovarian reserve
01/09 ROCHE : Presolicitation Notice - Reagents from Roche for CLIA Exome Sequencing
01/09 ROCHE : Special Notice - 66-- NOTICE OF INTENT TO SOLE SOURCE HCV & HIV Reagents..
01/09 FOUNDATION MEDICINE : FMI) Insider David Daly Sells 5,097 Shares
01/09 FOUNDATION MEDICINE, INC. : Results of Operations and Financial Condition, Other..
01/09 FOUNDATION MEDICINE, INC. (NAS : FMI) Files An 8-K Results of Operations a..
01/09 ROCHE : FDA grants Roche's cancer immunotherapy TECENTRIQ(atezolizumab) Priority..
01/09 ROCHE : FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizum..
01/08 FOUNDATION MEDICINE, INC. (NASDAQ : FMI) Files An 8-K Departure of Directors or ..
01/08 FOUNDATION MEDICINE : FMI) SVP Robert W. Hesslein Sells 4,682 Shares
01/08 OWNERSHIP CHANGE : The Insider Vincent Miller Sold 4773 shares of Foundation Med..
01/07 FOUNDATION MEDICINE : FMI) COO Steven J. Kafka Sells 8,390 Shares of Stock
01/06 FOUNDATION MEDICINE, INC. : Change in Directors or Principal Officers, Financial..
01/06 ROCHE : Approval of multi-product funding proposal with Roche
01/06 CHUGAI PHARMACEUTICAL : Findings from Chugai Pharmaceutical in the Area of Bone ..
01/06 CHUGAI PHARMACEUTICAL : PharmaMar and Chugai enter into a license and commercial..
01/06 CHUGAI PHARMACEUTICAL : New Chronic Kidney Disease Study Findings Recently Were ..
01/06 ROCHE : FDA approves Lucentis (ranibizumab injection) for myopic choroidal neova..
01/06 ROCHE : FDA Approves Genentech's Lucentis (Ranibizumab Injection) for Myopic Cho..
01/06 ROCHE : La Roche-sur-Yon - TC - Diagnosis of ventilation
01/06 HIV/AIDS : Stigma, Discrimination Are Real Killers – Ezechi
01/06 ROCHE : FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myo..
01/05 ROCHE : launches cobas c 513 analyzer and HbA1c Gen. 3 assay to meet increasing ..
01/05 FOUNDATION MEDICINE : Fmi) Coo Sold $144,341.73 in Stock
01/05 ROCHE : P-T grad playing key role at La Roche
01/04 ROCHE : Invitation to Roche’s Full Year Results 2016
01/03 Foundation Medicine, Inc. Stake Reduced by Senvest Management LLC
01/03 Foundation Medicine Inc. (Fmi) Issues Quarterly Earnings Results
01/02 New drug approvals fall to six-year low in 2016
2016 CHUGAI PHARMACEUTICAL : Bispecific Antibody "Emicizumab" for Hemophilia A Meets ..
2016 Foundation Medicine Receives FDA Approval of FoundationFocus™ CDxBRCA a..
2016 EXCLUSIVE - J&J DISCUSSING BREAKING : sources
2016 ROCHE : Breast cancer drug rejected for NHS use on cost-benefit grounds
2016 GLENMARK PHARMACEUTICALS : Gets fda nod for leukaemia treatment drug
2016 ROCHE : Rehabilitation of an old waste storage center
2016 ROCHE : s emicizumab haemophilia drug succeeds in phase III trial
2016 ROCHE : Positive Phase III Results of Genentech's Investigational Medicine Ocrev..
2016DJRoche Says Hemophilia Drug Reduces Bleeding in Late-Stage Trial
2016 ROCHE : Positive Phase III results for Roche's investigational medicine OCREVUS®..
2016 Roche's emicizumab haemophilia drug succeeds in trial
2016 ROCHE : emicizumab for haemophilia A meets primary endpoint in phase III study
2016 GENENTECH : ’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase..
2016 ROCHE : Positive Phase III results for Roche’s investigational medicine OC..
2016 ROCHE : Positive Phase III Results of Genentech’s Investigational Medicine..
2016 CHUGAI PHARMACEUTICAL : New Chemical Research Findings Has Been Reported by Inve..
2016 ROCHE : FDA Extends Review of Application for OCREVUS (Ocrelizumab)
2016 FOUNDATION MEDICINE, INC. (NASDAQ : FMI) Files An 8-K Other Events
2016 FOUNDATION MEDICINE, INC. : Other Events (form 8-K)
2016 ROCHE : FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
2016 CHUGAI PHARMACEUTICAL : ACTEMRA SC Injections Win a Prize of'WorldStar Award 201..
2016 CHUGAI PHARMACEUTICAL : Anti-Influenza Drug, Tamiflu Filed for Additional Dosage..
2016 ROCHE : CHMP recommends EU conditional approval of Roche's Alecensa (alectinib) ..
2016 DPharm Europe Returns to London With Global Examples of Innovation in Clinica..
2016 ROCHE : Sign materials
2016 ROCHE : Topographical services
2016 ROCHE : Announces Termination Of 2013 Development, Commercialization And License..
2016DJPRESS RELEASE : CHMP Recommends EU Conditional Approval of Roche's Alecensa (ale..
2016 PACIFIC BIOSCIENCES OF CALIFORNIA : PacBio Announces Termination of Agreement wi..
2016 ROCHE : Diagnostics Operations Assigned Patent
2016 FDI from the US rises 55.4 percent
2016 ARGOS THERAPEUTICS : ARGS) Appoints Ralph Snyderman and Irackly Mtibelishvily to..
2016 ARGOS THERAPEUTICS : Appoints Dr. Ralph Snyderman and Irackly Mtibelishvily to t..
2016 ROCHE : First-In-Human Assessment of PRX002, Prothenas Anti-Alpha Synuclein Anti..
1  2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ( CHF)
Sales 2016 51 079 M
EBIT 2016 17 585 M
Net income 2016 11 225 M
Debt 2016 11 030 M
Yield 2016 3,58%
P/E ratio 2016 18,55
P/E ratio 2017 16,67
EV / Sales 2016 4,27x
EV / Sales 2017 3,97x
Capitalization 206 856 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 283  CHF
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.204 641
JOHNSON & JOHNSON-0.53%311 773
ROCHE HOLDING LTD.2.75%204 641
PFIZER INC.0.12%197 343
NOVARTIS AG-1.48%189 749
MERCK & CO., INC.5.89%171 880
More Results